United States Drug Patent 3,886,277: Claim Scope, Expiration, FDA Status, and Patent Landscape

U.S. Patent No. 3,886,277 covers topical and shampoo-based methods for controlling visible dandruff with 5,7-dichloro-8-hydroxyquinoline, also known as chlorquinaldol or 5,7-dichloro-8-quinolinol. The patent issued in 1975 and its pre-1995 patent term expired no later than 17 years after issuance, placing the patent in the public domain. Its claims are no longer an exclusivity barrier to commercial products, although modern products would still require an independent FDA regulatory basis.

What does U.S. Patent 3,886,277 protect?

The patent protects a therapeutic use rather than a composition per se. Its independent claims require:

A human scalp and hair affected by visible dandruff.
Application of a composition containing:
- 5,7-dichloro-8-hydroxyquinoline; and
- a non-toxic, pharmaceutically acceptable carrier; or
Shampooing with an anionic, cationic, or amphoteric detergent composition containing the active ingredient.

The claims do not require a particular brand, dosage form, surfactant, fragrance, preservative, viscosity, packaging system, or manufacturing process.

Claim group	Subject matter	Key limitations
Claim 1	General topical method	Human hair and scalp; visible dandruff; carrier; active ingredient in an effective amount
Claims 2-4	Dependent concentration ranges	0.05%-5.0%; 0.01%-5.0%; or 0.5%-2.0% by weight
Claim 5	Shampoo method	Anionic, cationic, or amphoteric detergent composition
Claims 6-8	Shampoo concentration ranges	0.05%-5.0%; 0.1%-5.0%; or 0.5%-2.0% by weight
Claim 9	Treatment quantity	5-20 grams of the active ingredient, as written
Claim 10	Two-treatment regimen	The claimed 5-20 grams applied in two consecutive treatments
Claim 11	Six-week regimen	Twice weekly for two weeks, then once weekly for four weeks

The patent does not claim the chemical compound in isolation. It claims the use of that compound in an anti-dandruff treatment. A party would therefore need to practice the claimed human treatment method to implicate the patent.

What chemical is covered by the patent?

5,7-Dichloro-8-hydroxyquinoline is a substituted hydroxyquinoline. It is also identified in the literature as chlorquinaldol and 5,7-dichloro-8-quinolinol. The patent uses the chemical name rather than a broader Markush formula or a genus covering related quinoline compounds.

That narrow chemical definition limits literal infringement. A product containing a different anti-dandruff active, including zinc pyrithione, selenium sulfide, salicylic acid, sulfur, ketoconazole, or coal tar, would not satisfy the active-ingredient limitation merely because it treated the same condition.

The patent also does not claim all hydroxyquinolines. A structurally related compound would require a separate infringement analysis under the doctrine of equivalents, subject to prosecution-history estoppel and the usual limitations on expanding a specifically claimed chemical structure.

How do the concentration claims compare?

Claims 2, 3, and 4 are overlapping dependent claims with different concentration ranges.

Claim	Range	Practical scope
Claim 2	0.05%-5.0%	Broad range
Claim 3	0.01%-5.0%	Broadest numerical range
Claim 4	0.5%-2.0%	Narrower preferred range

Claim 3 encompasses the entire range in claim 2 because 0.01% is lower than 0.05% and the upper limit remains 5.0%. Claim 4 falls within both broader ranges.

The same structure appears in claims 6-8:

Claim	Range	Practical scope
Claim 6	0.05%-5.0%	Broad shampoo range
Claim 7	0.1%-5.0%	Intermediate range
Claim 8	0.5%-2.0%	Narrower range

A composition at 1.0% active would fall within all applicable ranges. A composition at 0.03% would fall within claim 3, but not claims 2 or 4. A composition at 3.0% would fall within claims 2 and 3, but not claim 4.

The specification and prosecution history would control whether the percentages refer to the finished composition, the aqueous phase, or another formulation basis. On the claim language supplied, the natural reading is weight percent of the composition.

What formulations are protected by U.S. Patent 3,886,277?

The patent reaches a wide range of topical and shampoo vehicles, provided the claimed ingredients and use limitations are met.

Topical formulations

Claim 1 can cover a cream, lotion, gel, ointment, solution, suspension, or other topical preparation if it includes a non-toxic, pharmaceutically acceptable carrier and is applied to the affected scalp and hair.

The claim does not require a detergent. A leave-on lotion could fall within claim 1 even though it would not satisfy the shampoo-specific limitations in claim 5.

Shampoo formulations

Claim 5 requires a detergent composition. It expressly identifies anionic, cationic, or amphoteric detergents. The claim therefore reaches shampoos based on different surfactant classes, including combinations of surfactants, so long as the product contains the claimed active ingredient and is used to shampoo affected human hair and scalp.

The claim does not expressly identify nonionic detergents. A shampoo containing only a nonionic detergent would raise a claim-construction issue under claim 5, although claim 1 could still be relevant if the composition had a qualifying pharmaceutically acceptable carrier.

Formulation features not claimed

The patent does not expressly protect:

Specific surfactant molecules.
Encapsulation or controlled release.
Particle-size specifications.
Solubilization systems.
pH ranges.
Conditioning agents.
Fragrance systems.
Preservatives.
Packaging.
Manufacturing equipment.
A specific commercial product.

Those features could have been protected in separate applications, but they are not present in the claims supplied for Patent 3,886,277.

When did U.S. Patent 3,886,277 lose exclusivity?

U.S. Patent 3,886,277 issued on May 27, 1975. For a pre-June 8, 1995 U.S. patent, the ordinary patent term was 17 years from issuance, subject to any applicable terminal disclaimer or patent-term adjustment rules. On that basis, the patent expired no later than May 27, 1992. [1][2]

Event	Date or status
Patent issued	May 27, 1975
Governing term framework	17 years from issuance for the pre-1995 patent
Ordinary expiration	May 27, 1992
Current status	Expired
Current enforceability	No enforceable patent exclusivity

The patent cannot support a current injunction, damages claim, Paragraph IV dispute, or royalty demand based on ordinary patent rights. Patent expiration places the claimed method in the public domain.

What is the Orange Book status of Patent 3,886,277?

Patent 3,886,277 is not a current Orange Book exclusivity asset. The Orange Book lists patents submitted for approved drug products, primarily under the FDA’s approved drug application framework. A decades-old method patent covering an anti-dandruff treatment does not create current Orange Book protection by itself. [3]

The patent also does not establish FDA approval of chlorquinaldol for dandruff. Patentability and FDA marketing authorization are separate questions.

For over-the-counter dandruff products, the relevant FDA regulatory framework includes the FDA’s dandruff drug products monograph provisions. The recognized anti-dandruff active ingredients include agents such as coal tar, pyrithione zinc, salicylic acid, selenium sulfide, and sulfur. Chlorquinaldol is not identified in the current dandruff active-ingredient provisions cited in 21 C.F.R. Part 358. [4]

As a result, the patent’s expiration removes patent risk but does not automatically make a chlorquinaldol dandruff product lawful for U.S. marketing. A current product would need an applicable monograph pathway, an approved application, or another legally valid FDA route.

Are there Paragraph IV challenges or generic launch barriers?

No current Paragraph IV challenge should be expected against Patent 3,886,277 because the patent expired decades ago. Paragraph IV certifications address patents listed for an approved drug application and are relevant to abbreviated new drug applications while listed patents remain operative. [5]

The principal current barriers are regulatory and commercial rather than patent-based:

FDA eligibility of chlorquinaldol as an anti-dandruff active.
Safety and effectiveness data.
Product labeling.
Manufacturing controls.
Stability and preservative data.
Consumer acceptance.
Availability of a lawful U.S. marketing pathway.

A manufacturer could formulate a product within the historic claim ranges without facing a live claim of Patent 3,886,277. The manufacturer would still need to avoid false or unsupported drug claims and comply with applicable FDA requirements.

What patent litigation affects U.S. Patent 3,886,277?

The supplied record establishes the patent and its claims but does not identify a current infringement action, settlement, consent judgment, terminal disclaimer, reissue, or extension affecting enforceability. Because the patent expired around 1992, any historic litigation would have no continuing exclusionary effect unless it involved separate patents or contractual obligations.

Patent expiration also eliminates the practical value of a prior settlement that purported to restrict conduct solely during the patent term. Contractual obligations could survive separately, but they would not arise from the patent claims alone.

How strong was the patent estate?

The patent was commercially meaningful when in force because it combined a defined active ingredient with a defined therapeutic use. Its claim strength had several limitations:

Strengths

The method claims directly targeted human dandruff treatment.
Claim 3 covered a low concentration down to 0.01%.
Claim 5 covered multiple detergent classes.
Claims 10 and 11 addressed treatment regimens, not only composition.
The active ingredient was chemically specific, making the claims relatively clear to apply to products using that compound.

Weaknesses

The patent did not claim the active compound itself.
It did not claim a broad class of anti-dandruff compounds.
The phrase "amount sufficient to provide effective anti-dandruff control" is functional and may invite proof disputes.
"Visible dandruff" and "affected therewith" introduce factual questions concerning diagnosis and treatment.
The claims depend on actual use on humans, which can complicate proof against manufacturers that sell products without directing a specific use.
Claims 2-4 and 6-8 contain substantial numerical overlap.
Claim 9 appears internally unusual because it states that 5-20 grams of the active ingredient is applied, while the earlier claims focus on percentages in a composition. If construed literally, the quantity is exceptionally high for a topical anti-dandruff product. If the intended meaning was 5-20 grams of composition, the claim text would not say so.

The claim set is therefore narrower than a composition patent covering every product that contains chlorquinaldol.

What prior-art and invalidity issues would have mattered?

The principal validity issues would have been novelty and obviousness under the patent law applicable at the time, now reflected in 35 U.S.C. §§ 102 and 103. [6]

Relevant prior art would likely have included:

Earlier anti-dandruff compositions.
Hydroxyquinoline antiseptic or antifungal uses.
Shampoo formulations containing related quinoline compounds.
Treatment regimens for seborrheic dermatitis or dandruff.
Evidence concerning the concentration and clinical effectiveness of chlorquinaldol.

Claim 1 requires the combined use of chlorquinaldol, a carrier, and effective anti-dandruff treatment. A prior reference disclosing the compound for another dermatological use would not necessarily anticipate the dandruff method, but it could contribute to an obviousness challenge when combined with anti-dandruff literature.

Claims 10 and 11 would be vulnerable if the treatment schedule merely reflected routine clinical optimization without evidence of an unexpected result. Claims 2-4 and 6-8 would depend on whether the claimed concentration ranges represented a patentable selection from known ranges and whether the specification supported the full breadth of the ranges.

Those historical validity questions no longer affect commercial freedom to operate because the patent has expired.

How does this patent compare with modern anti-dandruff patent strategies?

Modern anti-dandruff portfolios generally rely on multiple layers of protection rather than a single use patent.

Protection type	Patent 3,886,277	Typical modern strategy
Active compound	No	Compound or salt claims where available
Broad composition claim	Limited	Formulation and excipient combinations
Shampoo vehicle	Yes, functionally	Surfactant, deposition, and conditioning systems
Treatment method	Yes	Specific disease, dose, frequency, and patient subgroup
Delivery technology	No express claim	Encapsulation, particles, and controlled deposition
Manufacturing process	No express claim	Process, crystallization, and scale-up claims
Regulatory exclusivity	None	NDA exclusivity or other regulatory protections
Patent status	Expired	Active portfolios may extend beyond launch

The 1975 patent illustrates a single-use-method approach. A current competitor would typically assess compound, formulation, process, delivery, and regulatory rights separately.

What generic or competing-product launch risks exist?

Patent risk from Patent 3,886,277 is zero because the patent is expired. A launch assessment would instead focus on:

Whether chlorquinaldol can lawfully be marketed for dandruff in the United States.
Whether the proposed labeling creates an unapproved new drug.
Whether the active ingredient appears in an applicable OTC monograph.
Whether a competitor owns later patents covering a formulation, delivery system, or manufacturing process.
Whether the product infringes trademark, trade dress, or confidential manufacturing rights.
Whether the formulation meets current safety, quality, stability, and labeling requirements.

A product using chlorquinaldol at 0.5%-2.0% would fall squarely within the historic preferred concentration range, but that fact has no adverse patent consequence today. It could matter only as historical evidence of the scope of the expired disclosure.

Does the patent create licensing value today?

Patent 3,886,277 has no remaining patent licensing value based on exclusivity. A license purporting to grant freedom from this expired patent would provide no current patent right that a manufacturer could not obtain independently from the public domain.

Potential commercial value could exist only in separate assets not contained in the patent claims, such as:

Know-how.
Manufacturing specifications.
Historical clinical data.
Trademarks.
Regulatory files.
Trade secrets.
Later patents.
Distribution rights.

Those assets must be analyzed independently of Patent 3,886,277.

Key Takeaways

U.S. Patent 3,886,277 covers methods of treating visible dandruff with 5,7-dichloro-8-hydroxyquinoline.
Claims 1-4 cover carrier-based topical compositions and concentration ranges.
Claims 5-11 cover detergent shampoos, dosage quantities, and treatment schedules.
The patent issued May 27, 1975 and expired no later than May 27, 1992.
It has no current blocking patent effect and should not create a Paragraph IV or Orange Book litigation risk.
The patent does not establish FDA approval of chlorquinaldol.
Current commercial risk is regulatory, formulation-specific, and potentially based on later patents, not Patent 3,886,277.
Claim 9 is unusually drafted because it appears to require 5-20 grams of the active ingredient rather than 5-20 grams of the finished shampoo.

FAQs

Is chlorquinaldol still protected by a U.S. patent?

Patent 3,886,277 does not provide current protection. Its patent term expired around 1992. Later patents would need to be reviewed separately for any surviving protection involving chlorquinaldol.

Can a company sell a 1% chlorquinaldol shampoo in the United States?

The expired patent would not prevent the sale. FDA regulatory status remains a separate issue because the patent does not establish that chlorquinaldol is an approved or monograph-compliant anti-dandruff active.

Does claim 5 cover a nonionic chlorquinaldol shampoo?

Claim 5 expressly identifies anionic, cationic, and amphoteric detergents. A composition based only on nonionic detergent would not clearly satisfy that limitation, although claim 1 could present a separate analysis if the carrier and method requirements were met.

Does applying a chlorquinaldol lotion infringe the shampoo claims?

No. A lotion would not ordinarily satisfy the detergent and shampoo limitations in claim 5. It could have been evaluated under claim 1 during the patent term if it met the carrier, active-ingredient, human-use, and dandruff-treatment limitations.

What is the main commercial value of this patent today?

The patent has no current exclusivity value. Any remaining commercial relevance is historical or evidentiary, including formulation development, prior-art analysis, and assessment of chlorquinaldol’s earlier use in anti-dandruff products.

References

United States Patent No. 3,886,277. (1975). Anti-dandruff treatment method. United States Patent and Trademark Office.
United States Code, 35 U.S.C. § 154. Patent term and grant of patents.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
Code of Federal Regulations, 21 C.F.R. Part 358. External analgesic and antidandruff drug products.
United States Code, 21 U.S.C. § 355(j)(2)(A)(vii)(IV). Paragraph IV patent certification.
United States Code, 35 U.S.C. §§ 102-103. Novelty and nonobviousness.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	40231	Feb 14, 1967

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	297940	⤷ Start Trial
Belgium	710394	⤷ Start Trial
Switzerland	495749	⤷ Start Trial
Germany	1617836	⤷ Start Trial
Denmark	124586	⤷ Start Trial
Finland	47841	⤷ Start Trial
France	1574716	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 3,886,277

Summary for Patent: 3,886,277